The Relative Strength (RS) Rating for HealthEquity entered a new percentile Thursday, with a rise from 77 to 81.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an 80 or higher RS Rating as they begin their biggest price moves.
HealthEquity is working on a cup without handle with a 115.59 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company showed 10% earnings growth last quarter, while sales growth came in at 19%. Look for the next report on or around Jun. 3.
HealthEquity earns the No. 3 rank among its peers in the Commercial Services-Outsourcing industry group. Red Violet is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
